NAMS
NASDAQ · Biotechnology
Newamsterdam Pharma Co Nv
$18.90
+0.01 (+0.05%)
Financial Highlights (FY 2026)
Revenue
22.71M
Net Income
-205,735,412
Gross Margin
—
Profit Margin
-905.7%
Rev Growth
-38.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -1,002.9% | -902.6% | 8.2% | 7.5% |
| Profit Margin | -905.7% | -860.5% | 9.2% | 8.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 22.71M | 37.03M | 2.72B | 2.95B |
| Gross Profit | — | — | 806.06M | 871.89M |
| Operating Income | -227,779,259 | -334,204,977 | 222.76M | 221.95M |
| Net Income | -205,735,412 | -301,861,543 | 249.35M | 248.71M |
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -1,002.9% | -902.6% | 8.2% | 7.5% |
| Profit Margin | -905.7% | -860.5% | 9.2% | 8.4% |
| Rev Growth | -38.7% | -38.7% | +24.9% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.26B | 1.36B |
| Total Equity | — | — | 1.76B | 1.83B |
| D/E Ratio | — | — | 0.72 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -227,586,806 | -352,473,859 | 355.91M | 385.93M |
| Free Cash Flow | — | — | 147.67M | 144.03M |